Form 4: Barinthus Biotherapeutics CEO William Enright Acquires 600,000 Share Options

William Enright, CEO of Barinthus Biotherapeutics plc, reports the acquisition of 600,000 share options exercisable at $1, vesting in three annual installments starting February 3, 2026.

Summary

• William Enright, the CEO of Barinthus Biotherapeutics plc, filed a Form 4 on February 5, 2025.
• The filing reports a transaction that occurred on February 3, 2025, where Enright acquired 600,000 share options.
• These options have an exercise price of $1.
• The options vest in three equal annual installments, with the first installment vesting on February 3, 2026.
• The options expire on February 3, 2035.
• The ordinary shares underlying the options may be represented by American Depositary Shares (ADS), with each ADS currently representing one ordinary share.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of options by the CEO is mildly positive, suggesting confidence, but it's not a strong indicator.

Positives

• The acquisition of share options by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders may view the CEO's acquisition of share options as a positive signal.

Key Dates